US FDA delays decision on SpringWorks Therapeutics' tumor treatment
05/06/2023 11:42
June 5 (Reuters) - The U.S. Food and Drug Administration
(FDA) has extended its decision for SpringWorks Therapeutics
Inc's SWTX.O tumor treatment by three months, the company said
on Monday.
The previous action date of Aug. 27 has been extended as the
health regulator required more time to review additional data,
according to the company.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shounak
Dasgupta)
((Sriparna.Roy@thomsonreuters.com))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN